SilverbergS.J., BilezikianJ.P.Incipient primary hyperparathyroidism: a “forme fruste” of an old disease.J Clin Endocrinol Metab2003; 88: 5348–52.
2.
SilverbergS.J., ShaneE., JacobsT.P., SirisE.S., BilezikianJ.P.A ten-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.N Engl J Med1999; 341: 1249–55.
3.
RubinM.R., BilezikianJ.P., McMahonD.J.. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.J Clin Endocrinol Metab2008; 93: 3462–70.
4.
AmbroginiE., CetaniF., CianferottiL.. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial.J Clin Endocrinol Metab2007; 92: 3114–21.
5.
BilezikianJ.P., PottsJ.T., FuleihanG.E.H.. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.J Clin Endocrinol Metab2002; 87: 5353–61.
6.
BilezikianJ.P., KhanA.A., PottsJTJr.; Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.J Clin Endocrinol Metab2009; 94: 335–9.
7.
MollerupC.L., VestergaardP., FrøkjaerV.G., MosekildeL., ChristiansenP., Blichert-ToftM.Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study.BMJ2002; 325: 807.
8.
SouberbielleJ.C., Lawson-BodyE., HammadiB., SarfatiE., KahanA., CormierC.The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects.J Clin Endocrinol Metab2003; 88: 3501–4.
9.
RubinM.R., LeeK.H., McMahonD.J., SilverbergS.J.Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.J Clin Endocrinol Metab2003; 88: 1174–8.
10.
ZanchettaJ.R., BogadoC.E.Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.J Bone Miner Res2001; 16: 189–90.
11.
ChowC.C., ChanW.B., LiJ.K.Y.. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.J Clin Endocrinol Metab2003; 88: 581–7.
12.
KhanA.A., BilezikiamJ.P., KungA.W., AhmedM.M., DuboisS.J., HoA.Y.. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.J Clin Endocrinol Metab2004; 89: 3319–25.
13.
ScillitaniA., GuarnieriV., BattistaC.. Primary Hyperparathyroidism and the Presence of Kidney Stones Are Associated with Different Haplotypes of the Calcium-Sensing Receptor.J Clin Endocrinol Metab2007; 92: 277–83.
14.
BlockG.A., MartinK.J., de FranciscoA.L.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.N Engl J Med2004; 350: 1516–25.
15.
ShobackD.M., BilezikianJ.P., TurnerS.A.. The calcimimetic Cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.J Clin Endocrinol Metab2003; 88: 5644–9.
16.
StechmanM.J., LohN.Y., ThakkerR.V.Genetics of hypercalciuric nephrolithiasis: renal stone disease.Ann N Y Acad Sci2007; 1116: 461–84.
17.
BushinskyD.A., LaplanteK., AsplinJ.R.Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats.Kidney Int2006; 69: 1586–92.
18.
PeacockM., BilezikianJ.P., KlassenP.S.. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.J Clin Endocrinol Metab2005; 90: 135–41.
19.
KhanA., GreyA., ShobackD.Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.J Clin Endocrinol Metab2009; 94: 373–81.
20.
VitaleC., MarangellaM., VarvelloG.. Effects of parathyroidectomy on citrate excretion in patients with primary hyperparathyroidism and calcium nephrolithiasis.Ital J Mineral Electrolyte Metab1992; 6: 109–12.